Genetic analysis of treated and untreated phenylketonuria in one family


Abstract
We describe a family in which four subjects in two generations have a disorder of phenylalanine metabolism. Two first cousins had different biochemical presentations in the neonatal period. The older child was thought to have a more severe form of phenylketonuria (PKU), and the younger child a milder form. While carrying out family studies we discovered that their mutual grand-father and his older unmarried brother, both of normal intelligence, had a marked and previously undiagnosed hyperphenylalaninaemia. DNA analysis using RFLP haplotypes has shown that there are four independent mutant PKU alleles in this family which are found on three haplotype patterns. None of the affected family members carries a previously defined mutation at the phenylalanine hydroxylase (PAH) locus and so DNA analysis was not able to explain the apparently different biochemical phenotypes in the affected members of this family.

It has been known for some time that there are various disorders of phenylalanine metabolism which arise from a reduction in the activity of the hepatic enzyme phenylalanine hydroxylase (PAH). At its most severe, there is virtually a complete loss in enzyme activity, causing blood phenylalanine concentrations to increase sometimes to levels above 3000 μmol/l and phenylketones to appear in the urine. Historically, this condition has been called 'classical' PKU and, if not treated with a low phenylalanine diet from very early in life, will result in severe and irreversible mental retardation.

In milder forms of the disorder, the biochemical picture at presentation is less dramatic because there is only a reduction in the activity of the enzyme. Blood phenylalanine concentrations can range between 240 and 1200 μmol/l and phenylketones are not always found in the urine. This condition is called persistent hyperphenylalaninaemia (HPA) and in its mildest form, when blood phenylalanine concentrations are less than 430 μmol/l, no dietary phenylalanine restriction is required. However, other infants have a more reduced capacity to metabolise phenylalanine and some phenylalanine restriction may be desirable, particularly in early infancy to ensure that blood phenylalanine concentrations do not rise to levels which would impair normal brain development. While carrying a more severe form of PKU, one of these infants had been found to have a high blood phenylalanine concentration which was persistent even after dietary restriction had been imposed. The blood phenylalanine concentration in this infant was above 1500 μmol/l, and unacceptably high levels of phenylalanine in the blood were maintained even after her mother had been placed on a low phenylalanine diet. She was then diagnosed with 'classical PKU' and her cousin, born in 1987, is known to have a milder form of the disorder. Both were diagnosed in the neonatal period. Their mutual grandfather, born in 1925, and his older unmarried brother also have significant hyperphenylalaninaemia which had been previously undiagnosed.

The purpose of the study was to see if RFLP haplotype data and the analysis of specific mutations might explain the apparent differences in biochemical phenotype in this family.

Methods
RFLP ANALYSIS AND HAPLOTYPE DETERMINATION
Leucocyte DNA from each family member was
digested with seven restriction enzymes: BglII, PvuII, EcoRI,MspI,XmnI,HindIII, and EcoRV. 19 PvuII and MspI each highlight two polymorphic sites. Agarose gel electrophoresis and transfer of DNA fragments to a nylon membrane (Hybond N, Amersham) were carried out using standard protocols. 20 Filters were hybridised overnight at 65°C with the cDNA probe PAH247 (kindly supplied by Dr Savio Woo, Houston, Texas) which had been radiolabelled with 32P according to the method of Feinberg and Vogelstein. 21 Filters were washed at 65°C for 15 minutes each with 2×SSC and 1×SSC.

TESTING FOR SPECIFIC MUTATIONS
Specific exons were amplified in a Perkin Elmer Cetus Thermocycler using exon specific primers 22 and AmpliTaq (Perkin Elmer). After purification, the amplified products were spotted onto Hybond N (Amersham) and hybridised with radiolabelled allele specific oligonucleotide (ASO) probes 13, 14 according to standard protocols. Primer sequences for amplifying exons 7 and 5 to test for the arginine to glutamine replacements associated with haplotypes 1 and 4 respectively 17 were determined from DiLella et al. 3 Sequences for the normal and mutant ASO probes were determined from Kwok et al. 23 Positive controls (kindly supplied by E Kunert, Leipzig, GDR, for the exon 5 and 7 mutations) were included in all hybridisations.

DETERMINATION OF BLOOD PHENYLALANINE CONCENTRATIONS
Capillary blood was collected onto filter paper and the phenylalanine concentration measured by a fluorometric assay. Plasma phenylalanine and tyrosine concentrations were measured by column chromatography.

Results
FAMILY HISTORY
A concise family pedigree showing the relationship between affected subjects is given in fig 1.

III.1 was born in 1972 and at 7 days of age her blood phenylalanine concentration was 580 μmol/l. This had increased to 2500 μmol/l at 15 days but phenylketones were not reported in the urine. For the first 18 months of her life, her phenylalanine intake was 40 to 50 mg/kg/day and her blood phenylalanine concentration was generally between 60 and 240 μmol/l. At 12 months of age she was challenged with cow’s milk for a few days (between 85 and 115 mg phenylalanine/kg/day) and her blood phenylalanine concentration rose from 240 to 1800 μmol/l after 60 hours. It was believed that this confirmed a diagnosis of ‘classical’ PKU. Until the age of 16 years she had a restricted phenylalanine intake. This varied from 44 to 50 mg/kg/day but there was doubt about her compliance particularly in late childhood. Up to the age of 10 years her blood phenylalanine concentrations were generally between 350 and 550 μmol/l. Between 10 and 16 years they were between 650 and 900 μmol/l. Her physical and mental development are normal (at 12 years: verbal IQ 95, performance IQ 104, reading skills, accuracy score, Neal test 10 years 8 months, comprehensive score 12 years).

III.4, born in 1987, has a mild form of the condition. At 8 days of age his blood spot phenylalanine result was 350 μmol/l and this increased to 650 at 34 days of age when some dietary phenylalanine restriction was started. For his first year of life his phenylalanine intake was 75 mg/kg/day and his blood phenylalanine concentration during this time was consistently between 300 and 500 μmol/l. From two years of age he has been allowed an unrestricted dietary intake and his blood phenylalanine concentrations have been between 450 and 750 μmol/l. His physical and mental development are normal.

I.2 and I.3 were born in 1925 and 1923, respectively. Initially I.2 was studied biochemically and genetically to determine which grandparent was a carrier of the mutant PKU gene. He was found to have a significant hyperphenylalaninaemia which had not been previously diagnosed. His fasting midday phenylalanine concentration was 1020 μmol/l and the tyrosine was 73 μmol/l. His older unmarried brother, I.3, had a random blood spot phenylalanine concentration of 860 μmol/l. Both men are apparently of normal intelligence. I.2 had held desk jobs requiring numerical skills in his working life.

INHERITANCE OF HAPLOTYPES AT THE PAH LOCUS
Fig 2 summarises the inheritance of the haplotypes at
the phenylalanine hydroxylase locus in the complete family. Haplotype numbers are the same as those used by Chakraborty et al. RFLP analysis has shown that in this family there may be as many as four independent PKU mutations associated with three different haplotype patterns. The children are genetically different from each other and from their grandfather because they all have different combinations of haplotype patterns at the PAH locus. However, they all have one mutant haplotype 4 allele in common and gene tracking has shown that the affected children inherited this mutant gene from their grandfather via their parents who are brother and sister (II.1 and II.2). Gene tracking using RFLP haplotype patterns has also shown that II.7 inherited the mutant haplotype 4 allele from her father (I.2) and that II.5 and II.6 inherited the mutant haplotype 1 allele.

SPECIFIC POINT MUTATIONS
Amplification of exons 5, 7, and 12 and hybridisation of dot blots with allele specific oligonucleotide probes showed that none of the affected subjects in this family carried any of the mutations associated with haplotypes 1, 2, 3, and 4 in other populations. In addition, the exon 9 mutation found on haplotype 10 in two German families does not occur in this family, for an altered MspI site was not observed.

BIOCHEMICAL RESULTS
The fasting midday phenylalanine/tyrosine ratios (fig 3) confirmed carrier status in the parents of the children although it was interesting to note that only the father of the child with the milder form of the disorder had a result well into the heterozygote range, all others being just within the range of probability that they carry a mutant allele. II.6 had a random blood spot phenylalanine concentration of 135 μmol/l which was within the adult reference range.

Discussion
Molecular cloning of the phenylalanine hydroxylase gene and the identification of specific mutations within the gene has allowed direct analysis of this locus in the various types of hyperphenylalaninaemia. In all populations studied, the majority of mutant alleles has occurred on just four haplotypes, numbered 1 to 4. Specific mutations in linkage disequilibrium with haplotypes 2 and 3 in the Danish population have been defined, a point mutation at exon 12 occurring on haplotype 2 and a splice mutation at the intron/exon junction of exon 12 occurring on haplotype 3. Both mutations lead to a complete loss of enzyme activity and so in the Danish study patients who had any combination of mutant haplotype 2 and 3 invariably had a more severe form of the disorder. The tight linkage between haplotype 3 and the splicing mutation has also been found in other populations; however, with each of the other common haplotypes more than one mutation can account for a reduction in or absence of enzyme activity. In the Swiss population, for example, the specific mutations defined in exons 7 and 5 were found on only 72% and 33% of mutant haplotype 1.
and 4 alleles respectively, and in PKU patients in the south west of England, the point mutation in exon 12 was found on both haplotype 1 and 2 mutant alleles.

In the family reported here, there are four subjects in two generations who have compromised phenylalanine metabolism. Although there may be as many as four independent mutations on three different haplotype patterns in this family, none of the mutant alleles carries any of the mutations already defined (unpublished observations). III.1, in particular, who is believed to have a more severe form of the disorder has neither of the exon 12 mutations which results in a complete loss in enzyme activity. This was not unexpected since she did not have a haplotype 2 or 3 mutant allele and to date haplotype 5 has no associated point mutation. It can only be concluded that all of the mutant alleles in this family associated with haplotypes 1, 4, and 5 carry mutations which have not yet been defined and so genetic analysis alone has not been able to explain the apparent differences in biochemical phenotype.

Biochemical tests are available for discriminating between PKU and HPA and these range from oral or intravenous load tests to evaluating the activity of the enzyme in vitro after a liver biopsy or in vivo using labelled substrate and measuring the formation of labelled products. These tests are highly invasive or require sophisticated laboratory equipment and none has been carried out on affected subjects in the family reported here.

Because the two children were diagnosed in the neonatal period, both have been treated with a restricted phenylalanine intake in early infancy and childhood and their mental development has not been impaired. Regarding the two older men, however, it is curious that they are of apparently normal intelligence despite the fact that their blood phenylalanine concentrations are in a range that would normally be associated with some degree of mental impairment. Undoubtedly they carry a mutation of a less deleterious kind on one of their mutant alleles, but, in addition, one could speculate that their blood phenylalanine levels were lower in infancy and early childhood than they are now in their seventh decade of life. This could have arisen either because their dietary phenylalanine intake was unknowingly restricted at a critical period of brain development or because their hydroxylating systems have become less efficient with age. Scriver et al reported that normal plasma phenylalanine values in young and adult subjects are similar to those in the neonatal period; however, in persons in whom the hydroxylating system is already considerably compromised, it is possible that it becomes less efficient with advancing age. Only regular blood sampling over many years of those subjects with persistent, mild hyperphenylalaninaemia would provide an answer.

Clearly, this becomes an important consideration in relation to females who have had mild persistent hyperphenylalaninaemia since the neonatal period but in whom dietary phenylalanine restriction was not considered necessary to ensure their own normal brain development. If their blood phenylalanine concentration can increase with age, it may become sufficiently high in their third or fourth decade of life to affect adversely the development of a fetus and thereby result in an infant being born with the syndrome of maternal PKU. Regular monitoring of blood phenylalanine concentrations of even the mildest forms of PKU in females should be considered essential.

MJO was supported by a grant from the South Western Regional Health Authority. We are grateful to Dr E Kunert, Leipzig, for making available positive controls for the exon 5 and 7 mutations and to Mr Paul Rutland, London, for the normal haplotype 4 ASO probe.


18 Avivad S, Cohen BE, Woo SLC, Shiloh Y. A specific deletion within the phenylalanine hydroxylase gene is common to most Yemenite Jewish phenylketonuric patients. *Am J Hum Genet* 1987;41:205A.


